NEWS

2026723

Congress Keiichi Fukuda, CEO, to Present 52-Week Topline Results from the LAPiS Study in an Invited Lecture at the ESC Congress 2026

2026612

PR Heartseed, World's First Clinical Trial of Catheter Administration of iPSC-Derived Cardiomyocyte Spheroids: First Patient Dosed

202668

Congress Keiichi Fukuda, CEO, to Speak at the 10th Cardiovascular Bioengineering (CVBE) Symposium 2026

2026216

PR Notice Regarding Selection as a Constituent of the JPX Start-Up Acceleration 100 Index

202629

Seminar Keiichi Fukuda, CEO, to Speak at The 21st Edition of Roundtable Japan

2026119

Congress Keiichi Fukuda, CEO, to Speak at Keystone Symposia "iPSCs: Progress, Opportunities, and Challenges"

2025128

Congress Heartseed CMO Takehiko Kaneko to Speak at ISSCR International Symposium "PSC-Derived Therapies"

2025128

Congress Heartseed CMO Takehiko Kaneko to Speak at Global CVCT Forum - Discussing Clinical Trial Designs and Endpoints for Cell Therapy in Heart Failure -

2025114

PR Notice Regarding Completion of 30-Day Review for Clinical Trial Notification for Phase I/II Study of Cardiac Remuscularization Therapy HS-005 (Catheter Administration) Targeting Severe Heart Failure

2025911

PR Notice Regarding the New Partner for Delivery Catheter System for Allogeneic iPS Cell-Derived Cardiomyocyte Spheroids

1 2 3 4 5 6 7 8 9